Maternal and fetal outcomes among women with depression.
ABSTRACT To compare maternal and fetal outcomes among women with and without diagnosed depression at the time of delivery.
Hospital discharge data from the 1998-2005 Nationwide Inpatient Sample (NIS) were used to examine delivery-related hospitalizations for select maternal and fetal outcomes by depression diagnosis.
The rate of depression per 1000 deliveries increased significantly from 2.73 in 1998 to 14.1 in 2005 (p < 0.001). Women diagnosed with depression were significantly more likely to have cesarean delivery, preterm labor, anemia, diabetes, and preeclampsia or hypertension compared with women without depression. Fetal outcomes significantly associated with maternal depression were fetal growth restriction, fetal abnormalities, fetal distress, and fetal death.
These findings suggest that depression is associated with adverse maternal and fetal outcomes. Our results provide additional impetus to screen for depression among women of reproductive age, especially those who plan to become pregnant.
SourceAvailable from: Eynav Elgavish Accortt[Show abstract] [Hide abstract]
ABSTRACT: Complications related to preterm birth (PTB) and low birth weight (LBW) are leading causes of infant morbidity and mortality. Prenatal depression is a hypothesized psychosocial risk factor for both birth outcomes. The purpose of this systematic review was to examine evidence published between 1977 and 2013 on prenatal depression and risks of these primary adverse birth out-comes. A systematic search of the PUBMED and Psy-cINFO databases was conducted to identify studies testing the associations between prenatal depressive symptoms, or diagnoses of depression, and risk of PTB or LBW. We systematically selected 50 published reports on PTB and length of gestation, and 33 reports on LBW and BW. Results were reviewed by two independent reviewers and we evaluated the quality of the evidence with an established systematic review method, the Newcastle Ottawa Scale. We then undertook a narrative synthesis of the results following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Less than a quarter of 50 published reports found that prenatal depression was significantly associated with PTB or gestational age. In contrast, slightly more than half of the 33 reports found that prenatal depression was associated with LBW or BW. When weighing methodological features, we determined that the effects of prenatal depression on LBW are more consistent than effects on length of gestation or PTB. Although the evidence may not be strong enough to support routine depression screening for risk of adverse outcomes, screening to enable detection and timely treatment to reduce risk of postpartum depression is warranted. Further rigorous research on prenatal depression and adverse birth outcomes is needed.Maternal and Child Health Journal 12/2014; DOI:10.1007/s10995-014-1637-2 · 2.24 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: ZET: Dikkat çekici bir konu: Hamile ve depresyondaki kadınlara ilaç önerilmeli mi? Erkeklere kıyasla kadınlar daha fazla depresyon yaygınlık oranlarına sahiptir ve özellkle doğurganlık çağında dep-resyona daha da duyarlıdırlar. Depresyon oranları gebelik dönemindeki kadınlar için %20'lere kadar ulaşabilir. Aslında kadınları tedavi eden bir klinisyenin, kendisini annenin ve bebeğin gelişiminin korunması için en uygun yöntemi seçmeye çalışırken bulması oldukça muhtemeldir. Emniyet konuları ve doğumla ilgili olumsuz sonuçlar gebelikte anti-depresan kullanımı ile ilgili başlıca endişe alanlarıdır. Diğer taraftan, tedavi edilmemiş depresyon da anne ve bebek için sağlık komplikasyonlarına yol açma potansiyeline sahiptir. Ancak gebelikte antidepresan kullanımının muh-temel yan etkilerinin daha fazla vurgulandığı ama tedavi edilmemiş depresyonun o kadar önemsenmediği aşikardır. Halihazırdaki çalışmalar gebelik sırasında antidepresan kul-lanımının emniyetli olup olmadığına dair çelişkili sonuçlar ortaya koymaktadır dolayısıyla da mevcut verilerin yorum-lanması çok dikkatli bir şekilde yapılmalıdır. Ebeveynlerle birlikte karar verirken her iki seçeneğin de riskleri ve fay-daları göz önüne alınmalıdır. Anahtar sözcükler: Gebelik, antidepresan emniyeti, tera-tojenite, tedavi edilmemiş depresyon Journal of Mood Disorders 2011;1(3):118-25 ABS TRACT: A challenging issue: Should medications be prescribed to pregnant and depressed women? Women have higher prevalence rates of depression than men and they are particularly vulnerable to depression in childbearing years. The rates of depression can reach up to 20% of all women during pregnancy. Actually, physicians who treat women are likely to find themselves trying to choose the best option for protection of the mother and for the development of her child. Safety issues and negative birth outcomes are matters of concern with antidepressant use during pregnancy. Otherwise, untreated depression also has potential to cause health complications for both mother and infant. It is obvious that possible adverse effects of antidepressant use during pregnancy are more emphasized but adverse outcomes of untreated depression are underrated. Currently, studies exhibit conflicting results about antidepressant safety in pregnancy period so current data must be cautiously interpreted. The risks and benefits of both options must be taken into account in decision-making process with families. Ya zış ma Ad re si / Add ress rep rint re qu ests to: Elekt ro nik pos ta ad re si / E-ma il add ress: firstname.lastname@example.org Ka bul ta ri hi / Da te of ac cep tan ce: 2 Eylül 2011 / September 2, 2011 Bağıntı beyanı: N.A., E.O., M.G.: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemişlerdir..: The authors reported no conflict of interest related to this article.09/2011; 1(3):118-25. DOI:10.5455/jmood.20110902072926
[Show abstract] [Hide abstract]
ABSTRACT: To identify risk factors for and the consequences (several adverse perinatal outcomes) of physician-diagnosed major depression during pregnancy treated in specialised healthcare.BMJ Open 11/2014; 4(11):e004883. DOI:10.1136/bmjopen-2014-004883 · 2.06 Impact Factor